Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
Sponsor: Deciphera Pharmaceuticals, LLC
Summary
This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced/metastatic renal cell carcinoma (RCC), urothelial carcinoma, and castration-resistant prostate cancer.
Official title: An Open-label, Phase 1 Study of DCC-2812 Monotherapy in Participants With Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2025-08-27
Completion Date
2029-02
Last Updated
2026-08-18
Healthy Volunteers
No
Interventions
DCC-2812
Administered orally
Locations (8)
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
University of Michigan
Ann Arbor, Michigan, United States
Washington University School of Medicine
St Louis, Missouri, United States
Cleveland Clinic
Cleveland, Ohio, United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
Vanderbilt- Ingram Cancer Center
Nashville, Tennessee, United States
NEXT Oncology, Austin
Austin, Texas, United States
NEXT Oncology, San Antonio
San Antonio, Texas, United States